Oculis (NASDAQ:OCS) PT Lowered to $28.00

Oculis (NASDAQ:OCS - Get Free Report) had its price objective reduced by investment analysts at HC Wainwright from $29.00 to $28.00 in a report released on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target would indicate a potential upside of 133.72% from the stock's current price.

Several other brokerages have also commented on OCS. Chardan Capital restated a "buy" rating and issued a $30.00 price target on shares of Oculis in a research note on Tuesday, March 19th. Robert W. Baird dropped their price target on shares of Oculis from $64.00 to $35.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 19th. Finally, Wedbush reiterated an "outperform" rating and issued a $29.00 price objective on shares of Oculis in a report on Wednesday, March 6th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $29.14.

Oculis Stock Up 0.1 %

OCS stock traded up $0.01 during mid-day trading on Wednesday, hitting $11.98. 191,128 shares of the company were exchanged, compared to its average volume of 46,391. The firm has a fifty day simple moving average of $11.89 and a 200 day simple moving average of $11.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.29 and a quick ratio of 5.29. Oculis has a twelve month low of $9.05 and a twelve month high of $14.50.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.04. The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.28 million. Equities research analysts expect that Oculis will post -1.75 EPS for the current year.

Institutional Trading of Oculis

Several large investors have recently added to or reduced their stakes in the company. Barclays PLC purchased a new stake in shares of Oculis in the second quarter worth approximately $44,000. Wolverine Asset Management LLC bought a new stake in Oculis in the third quarter worth approximately $77,000. Compagnie Lombard Odier SCmA lifted its position in shares of Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock worth $1,053,000 after buying an additional 30,750 shares during the last quarter. abrdn plc bought a new stake in shares of Oculis during the 4th quarter worth about $15,980,000. Finally, Searle & CO. acquired a new position in Oculis in the 4th quarter valued at $112,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.